Cargando…

Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation

Loratadine (LORA), is a topical antihistamine utilized in the treatment of ocular symptoms of COVID-19. The study aimed to develop a Loratadine Nanostructured Lipid Carriers Ocugel (LORA-NLCs Ocugel), enhance its solubility, trans-corneal penetrability, and bioavailability. full-factorial design was...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelmonem, Rehab, Al-Samadi, Inas Essam Ibrahim, El Nashar, Rasha M., Jasti, Bhaskara R., El-Nabarawi, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448409/
https://www.ncbi.nlm.nih.gov/pubmed/36065090
http://dx.doi.org/10.1080/10717544.2022.2115164
_version_ 1784784055015833600
author Abdelmonem, Rehab
Al-Samadi, Inas Essam Ibrahim
El Nashar, Rasha M.
Jasti, Bhaskara R.
El-Nabarawi, Mohamed A.
author_facet Abdelmonem, Rehab
Al-Samadi, Inas Essam Ibrahim
El Nashar, Rasha M.
Jasti, Bhaskara R.
El-Nabarawi, Mohamed A.
author_sort Abdelmonem, Rehab
collection PubMed
description Loratadine (LORA), is a topical antihistamine utilized in the treatment of ocular symptoms of COVID-19. The study aimed to develop a Loratadine Nanostructured Lipid Carriers Ocugel (LORA-NLCs Ocugel), enhance its solubility, trans-corneal penetrability, and bioavailability. full-factorial design was established with 2(4) trials to investigate the impact of several variables upon NLCs properties. LORA-NLCs were fabricated by using hot melt emulsification combined with high-speed stirring and ultrasonication methods. All obtained formulae were assessed in terms of percent of entrapment efficiency (EE%), size of the particle (PS), zeta potential (ZP), as well as in-vitro release. Via using Design Expert® software the optimum formula was selected, characterized using FTIR, Raman spectroscopy, and stability studies. Gel-based of optimized LORA-NLCs was prepared using 4% HPMC k100m which was further evaluated in terms of physicochemical properties, Ex-vivo, and In-vivo studies. The optimized LORA-NLCs, comprising Compritol 888 ATO(®), Labrasol(®), and Span(®) 60 showed EE% of 95.78 ± 0.67%, PS of 156.11 ± 0.54 nm, ZP of −40.10 ± 0.55 Mv, and Qh6% of 99.67 ± 1.09%, respectively. Additionally, it illustrated a spherical morphology and compatibility of LORA with other excipients. Consequently, gel-based on optimized LORA-NLCs showed pH (7.11 ± 0.52), drug content (98.62%± 1.31%), viscosity 2736 cp, and Q12% (90.49 ± 1.32%). LORA-NLCs and LORA-NLCs Ocugel exhibited higher ex-vivo trans-corneal penetrability compared with the aqueous drug dispersion. Confocal laser scanning showed valuable penetration of fluoro-labeled optimized formula and LORA-NLCs Ocugel through corneal. The optimized formula was subjected to an ocular irritation test (Draize Test) that showed the absence of any signs of inflammation in rabbits, and histological analysis showed no effect or damage to rabbit eyeballs. C(max) and the AUC(0–24) were higher in LORA-NLCs Ocugel compared with pure Lora dispersion-loaded gel The research findings confirmed that NLCs could enhance solubility, trans-corneal penetrability, and the bioavailability of LORA.
format Online
Article
Text
id pubmed-9448409
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-94484092022-09-07 Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation Abdelmonem, Rehab Al-Samadi, Inas Essam Ibrahim El Nashar, Rasha M. Jasti, Bhaskara R. El-Nabarawi, Mohamed A. Drug Deliv Research Article Loratadine (LORA), is a topical antihistamine utilized in the treatment of ocular symptoms of COVID-19. The study aimed to develop a Loratadine Nanostructured Lipid Carriers Ocugel (LORA-NLCs Ocugel), enhance its solubility, trans-corneal penetrability, and bioavailability. full-factorial design was established with 2(4) trials to investigate the impact of several variables upon NLCs properties. LORA-NLCs were fabricated by using hot melt emulsification combined with high-speed stirring and ultrasonication methods. All obtained formulae were assessed in terms of percent of entrapment efficiency (EE%), size of the particle (PS), zeta potential (ZP), as well as in-vitro release. Via using Design Expert® software the optimum formula was selected, characterized using FTIR, Raman spectroscopy, and stability studies. Gel-based of optimized LORA-NLCs was prepared using 4% HPMC k100m which was further evaluated in terms of physicochemical properties, Ex-vivo, and In-vivo studies. The optimized LORA-NLCs, comprising Compritol 888 ATO(®), Labrasol(®), and Span(®) 60 showed EE% of 95.78 ± 0.67%, PS of 156.11 ± 0.54 nm, ZP of −40.10 ± 0.55 Mv, and Qh6% of 99.67 ± 1.09%, respectively. Additionally, it illustrated a spherical morphology and compatibility of LORA with other excipients. Consequently, gel-based on optimized LORA-NLCs showed pH (7.11 ± 0.52), drug content (98.62%± 1.31%), viscosity 2736 cp, and Q12% (90.49 ± 1.32%). LORA-NLCs and LORA-NLCs Ocugel exhibited higher ex-vivo trans-corneal penetrability compared with the aqueous drug dispersion. Confocal laser scanning showed valuable penetration of fluoro-labeled optimized formula and LORA-NLCs Ocugel through corneal. The optimized formula was subjected to an ocular irritation test (Draize Test) that showed the absence of any signs of inflammation in rabbits, and histological analysis showed no effect or damage to rabbit eyeballs. C(max) and the AUC(0–24) were higher in LORA-NLCs Ocugel compared with pure Lora dispersion-loaded gel The research findings confirmed that NLCs could enhance solubility, trans-corneal penetrability, and the bioavailability of LORA. Taylor & Francis 2022-09-05 /pmc/articles/PMC9448409/ /pubmed/36065090 http://dx.doi.org/10.1080/10717544.2022.2115164 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Abdelmonem, Rehab
Al-Samadi, Inas Essam Ibrahim
El Nashar, Rasha M.
Jasti, Bhaskara R.
El-Nabarawi, Mohamed A.
Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation
title Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation
title_full Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation
title_fullStr Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation
title_full_unstemmed Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation
title_short Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation
title_sort fabrication of nanostructured lipid carriers ocugel for enhancing loratadine used in treatment of covid-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448409/
https://www.ncbi.nlm.nih.gov/pubmed/36065090
http://dx.doi.org/10.1080/10717544.2022.2115164
work_keys_str_mv AT abdelmonemrehab fabricationofnanostructuredlipidcarriersocugelforenhancingloratadineusedintreatmentofcovid19relatedsymptomsstatisticaloptimizationinvitroexvivoandinvivostudiesevaluation
AT alsamadiinasessamibrahim fabricationofnanostructuredlipidcarriersocugelforenhancingloratadineusedintreatmentofcovid19relatedsymptomsstatisticaloptimizationinvitroexvivoandinvivostudiesevaluation
AT elnasharrasham fabricationofnanostructuredlipidcarriersocugelforenhancingloratadineusedintreatmentofcovid19relatedsymptomsstatisticaloptimizationinvitroexvivoandinvivostudiesevaluation
AT jastibhaskarar fabricationofnanostructuredlipidcarriersocugelforenhancingloratadineusedintreatmentofcovid19relatedsymptomsstatisticaloptimizationinvitroexvivoandinvivostudiesevaluation
AT elnabarawimohameda fabricationofnanostructuredlipidcarriersocugelforenhancingloratadineusedintreatmentofcovid19relatedsymptomsstatisticaloptimizationinvitroexvivoandinvivostudiesevaluation